Virus-like particles with FLAG-tagged envelope protein as a tetravalent dengue vaccine candidate

[1]  E. Park,et al.  Agglutination of Human Polyomaviruses by Using a Tetravalent Glycocluster as a Cross-Linker , 2020, ACS omega.

[2]  E. Park,et al.  Production of dengue virus-like particles serotype-3 in silkworm larvae and their ability to elicit a humoral immune response in mice , 2020, AMB Express.

[3]  H. Harapan,et al.  Dengue: A Minireview , 2020, Viruses.

[4]  David L. Smith,et al.  Past and future spread of the arbovirus vectors Aedes aegypti and Aedes albopictus , 2019, Nature Microbiology.

[5]  E. Konishi,et al.  High-throughput neutralization assay for multiple flaviviruses based on single-round infectious particles using dengue virus type 1 reporter replicon , 2018, Scientific Reports.

[6]  J. Galarza,et al.  Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature. , 2018, Vaccine.

[7]  T. Westling,et al.  Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy , 2018, The New England journal of medicine.

[8]  S. Swaminathan,et al.  Dengue envelope-based ‘four-in-one’ virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice , 2018, Scientific Reports.

[9]  Torsten Schwede,et al.  SWISS-MODEL: homology modelling of protein structures and complexes , 2018, Nucleic Acids Res..

[10]  Holger Hannemann,et al.  Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope , 2018, Virology Journal.

[11]  S. Swaminathan,et al.  Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo , 2018, Front. Microbiol..

[12]  R. Johnston,et al.  A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice , 2018, PLoS neglected tropical diseases.

[13]  A. Turrini,et al.  Transcriptome changes induced by arbuscular mycorrhizal fungi in sunflower (Helianthus annuus L.) roots , 2018, Scientific Reports.

[14]  M. Halloran,et al.  Antibody-dependent enhancement of severe dengue disease in humans , 2017, Science.

[15]  K. Morita,et al.  An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design , 2017, Journal of Virology.

[16]  K. Kawasaki,et al.  Development of a Japanese encephalitis virus-like particle vaccine in silkworms using codon-optimised prM and envelope genes , 2017, Heliyon.

[17]  E. Konishi,et al.  Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus , 2016, Scientific Reports.

[18]  P. Desprès,et al.  Recognition determinants of broadly neutralizing human antibodies against dengue viruses , 2015, Nature.

[19]  Eva Harris,et al.  Dengue , 2015, The Lancet.

[20]  E. A. Christian,et al.  Atomic-level functional model of dengue virus Envelope protein infectivity , 2013, Proceedings of the National Academy of Sciences.

[21]  John S. Brownstein,et al.  The global distribution and burden of dengue , 2013, Nature.

[22]  T. Vesikari,et al.  Characterization and immunogenicity of norovirus capsid-derived virus-like particles purified by anion exchange chromatography , 2012, Archives of Virology.

[23]  Poornima Tyagi,et al.  Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2 , 2012, Journal of Nanobiotechnology.

[24]  D. Fang,et al.  Induction of virus-neutralizing antibodies and T cell responses by dengue virus type 1 virus-like particles prepared from Pichia pastoris. , 2012, Chinese medical journal.

[25]  Mengfeng Li,et al.  Vaccination with dengue virus-like particles induces humoral and cellular immune responses in mice , 2011, Virology Journal.

[26]  Y. Modis,et al.  Crystal Structure of Dengue Virus Type 1 Envelope Protein in the Postfusion Conformation and Its Implications for Membrane Fusion , 2009, Journal of Virology.

[27]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[28]  J. Roehrig,et al.  Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells , 2001, Journal of Virology.

[29]  J. L. Swanson,et al.  Physical and Biological Properties of Dengue-2 Virus and Associated Antigens , 1970, Journal of virology.

[30]  R. Schlesinger,et al.  Studies on the nature of dengue viruses. I. Correlation of particle density, infectivity, and RNA content of type 2 virus. , 1965, Virology.